Herpes simplex virus type 1 and type 2 (HSV-1 and -2) are ubiquitous human pathogens belonging to the family of Herpesviridae. A common feature of herpes viruses is the establishment of long-term latent infections, with periods of recurring viral replication. HSVs cause recurrent infections of the nervous system located around the lips, in the eyes, in the mucous membrane of the oral cavity, and the genitals. Especially, genital herpes is an important sexually transmitted disease most commonly caused by HSV-2. HSV-2 causing serious systemic infection may be a risk factor for the transmission of human immunodeficiency virus (HIV). As a very effective treatment for HSVs, acyclovir is commonly used. 1) This agent is a synthetic nucleoside analog interfering with viral DNA replication after activation by viral thymidine kinase, but it is not always well tolerated, and rapid emergence of drug-resistant strains has been reported, particularly in immunocompromised patients.
2) It is therefore necessary search for alternative anti-herpetic agents of natural origin without severe adverse effects.
On the other hands, influenza is one of the most common infectious diseases in birds and mammals, with high rates of morbidity and mortality, 3) and it is a highly contagious, acute respiratory disease that affects all age groups. A major problem is that influenza viruses (IFV) show high genetic variability, owing to an antigenic drift in two viral surface glycoproteins, hemagglutinin and neuraminidase. 4) Infection of toxic strains of avian influenza viruses (H5N1) in humans, emerged in Hong Kong in 1997. Fortunately, the virus did not acquire the ability to spread through the human population. However, emergence of a novel virus strain might occur in future. Unexpectedly, a pandemic of new type of swine influenza (H1N1) occured in 2009. Presently, only two sialidase inhibitors (zanamivir and oseltamivir) and two M2 protein channel blockers (amantadine and remantadine) are available for clinical use as anti-influenza drugs, but resistance to these drugs has been reported.
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Therefore, it is also urgently necessary to establish a novel anti-influenza strategy.
In the course of our studies on evaluation of edible natural products for their antiviral effects, we discovered various polysaccharides with unique structures and action mechanisms in edible algae. For example, fucan sulfates from brown algae such as Sargassum horneri 8) and Undaria pinnatifida 9) showed potent antiviral activities against enveloped viruses such as HSV-1, HSV-2, and influenza A virus (IFV-A). In addition, calcium spirulan and nostoflan were isolated from Spirulina platensis, which grows in alkaline salty lakes and Nostoc flagelliforme, which grows in some arid and semiarid regions of China. They showed potent inhibitory effects on enveloped viruses. [10] [11] [12] Thus, edible algae are considered to be attractive materials for treatment of viral infectious diseases.
Aphanothece sacrum is a freshwater unicellular cyanobacterium indigenous to Japan. Recently, it has been aquacultured in Kogane River in Fukuoka Prefecture. This rare freshwater cyanobacteria is legally protected at its native habitat in Ezu Lake, Kumamoto Prefecture. The dried alga is used as an ordinary food item after soaking in water as well as a nutritional supplementary food. The dried algal cells contain substantial amounts of vitamin B 12 , and the contents of Ca, Fe, Cu, and Mn are higher than those of other edible seaweeds. 13, 14) Although the physicochemical respectively. Protein content was determined using a Bio-Rad protein assay kit (Bio-Rad Laboratories, K.K., Tokyo, Japan). Sulfate content was determined by using the rhodizonate method.
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Cell and viruses. Vero and MDCK cells were grown in MEM supplemented with 5% fetal bovine serum (FBS). HSV-2 (UW268 strain) and IFV-A (A/NWS/33, H1N1) were grown on Vero and MDCK cells respectively.
Evaluation for antiviral activity and cytotoxicity in vitro. In the cell growth inhibition studies, Vero and MDCK cells were cultured for 72 h in the presence of increasing amounts of tested sample. Viable cell yield was determined by trypan blue exclusion test. The inhibition data were plotted as dose-response curves, from which the 50% cell growth inhibitory concentration (CC 50 ) was obtained. In the antiviral tests, cell monolayers in 48-well plates were infected with virus at 0.1 plaqueforming unit (PFU) per cell at room temperature. After 1 h of viral infection, the monolayers were washed 3 times with phosphatebuffered saline (PBS) and incubated in maintenance medium (MEM plus 2% FBS) at 37 C. Samples were added during infection, and throughout incubation thereafter, or immediately after virus infection. The cell cultures were harvested 24 h post-infection (p.i.), and their virus yields were determined by plaque assay after 2 d of incubation. The 50% inhibitory concentration (IC 50 ), the concentration of sample that reduced plaque numbers by 50% in the treated cultures as compared with no-drug control, was obtained from a concentrationresponse curve. Antiviral activities were estimated by selectivity indices calculated from CC 50 and IC 50 values.
Time-of-addition experiments. Vero cell monolayers were infected with HSV-2 at 10 PFU per cell. MDCK cell monolayers were infected with IFV-A at 0.5 PFU per cell. ASWPH was added at a concentration of 100 mg/ml before viral infection for 3 h, during viral infection for 1 h, during viral infection and throughout incubation thereafter, immediately after infection, at 1 h p.i., at 3 h p.i., or at 6 h p.i. At 24 h p.i., the cell cultures were harvested and subjected to plaque assay.
Virus adsorption assay. The effect of ASWPH on virus adsorption to the host cells was evaluated by infectious center assay. For HSV-2, Vero cell suspensions, HSV-2 (1 PFU/cell), and ASWPH were precooled on ice for 2 h before mixing. After 1 h of incubation at 4 C, the cell suspensions were washed 3 times with ice-cold PBS to remove any unbound viruses and free compound. The cell pellets were diluted 10-fold with ice-cold PBS and immediately added to Vero cell monolayers in 35-mm dishes for plaque assay. For IFV-A, MDCK cell monolayers, IFV-A, and ASWPH were pre-cooled on ice for 2 h before infection at 4 C. After 1 h of incubation at 4 C, the cell monolayers were washed 3 times with ice-cold PBS and overlaid with agar medium for plaque assay. Virus yields were determined by plaque assay after 2 d of incubation.
Virus penetration assay. Cell monolayers pre-cooled for 2 h on ice were infected with HSV-2 or IFV-A at 4 C for 1 h in the absence of ASWPH. After they were washed 3 times with ice-cold PBS, cell monolayers were incubated at 37 C in a medium containing ASWPH. At 0, 0.5, 1, 2, 3, and 6 h after a temperature shift to 37 C, the cell monolayers were treated with a 40 mM citrate buffer (pH 3.0) for 1 min to inactivate any unpenetrated viruses, and then overlaid with medium for plaque assay.
Virucidal assay. To determine the effects of ASWPH on the direct inactivation of virus particles, HSV-2 or IFV-A (2 Â 10 4 PFU/100 ml) was treated with an equal volume of ASWPH at 37 C. After 0, 1, 2, 3, or 6 h, 100-fold dilutions of the mixture were added to cell monolayers for 1 h at room temperature. The cell monolayers were overlaid with medium for plaque assay.
Statistical analysis. The data are presented as mean AE SD. Differences between groups were analyzed by one-way analysis of variance (ANOVA)
Results and Discussion
Evaluation of separated fractions from A. sacrum for antiviral effects
The dried body of A. sacrum was extracted with EtOH, followed by extraction with hot H 2 O to give EtOH soluble extract (ASE) and aqueous extract (ASW) respectively. Because ASW was considered to contain large amounts of polysaccharides and/or proteins, it was treated with 4 vol of EtOH to precipitate macromolecular portions. Thus EtOH soluble (ASWS) and insoluble parts (ASWP) were obtained, and the latter fraction was further fractionated by dialysis (MWCO: 14,000) to dialyzable (ASWPL) and non-dialyzable (ASWPH) fractions.
The six fractions thus obtained from A. sacrum were evaluated for antiviral potency against HSV-2 and IFV-A. In general, a sample was regarded as possessing antiviral activity when its selectivity index (SI, CC 50 / IC 50 ) was higher than 10. As shown in Table 1 , the SI values for ASWP and ASWPH against HSV-2 were 4,700 and higher than 20,000, respectively, when they were added to the medium at the same time as virus infection (experiment A). On the other hand, when they were added to the medium immediately after virus infection (experiment B), their values were less than those in experiment A. This suggests that the active fractions inhibit early stages of viral replication, such as viral adsorption and penetration. On the other hand, the SI values of ASWPH against IFV-A were 7,100 and 6,200 in experiments A and B respectively, almost equal to those of oseltamivir. ASWPL showed no anti-HSV-2 or -IFV-A activity.
Chemical characterization of ASWPH
In order to characterize ASWPH obtained as a macromolecular fraction, its chemical components were analyzed. ASWPH was found to contain neutral sugars (33.0%), uronic acids (3.4%), and proteins (26.4%) by colorimetric methods, phenol-sulfuric acid, m-hydro-xydiphenyl, and Bradford methods, respectively. In addition, sulfate group was also detected in this fraction and its content was estimated to be 2.5% by rhodizonate method. Therefore, ASWPH was found to contain polysaccharides and proteins with sulfate ester.
Determination of antiviral targets of ASWPH
In order to determine the most sensitive stages of viral replication for ASWPH, time-of-addition experiments were performed. In these experiments, Vero and MDCK cells were infected with HSV-2 at a multiplicity of infection (MOI) of 10 and IFV-A at an MOI of 0.5. As shown in Fig. 1 , ASWPH (100 mg/ml) suppressed progeny HSV-2 production most efficiently when it was added at the time of virus infection and throughout incubation thereafter. By contrast, pretreatment of Vero cells with ASWPH showed no inhibitory effect. It is noteworthy that robust anti-HSV-2 activity was also observed when ASWPH was added to the medium only during viral infection, and that ASWPH maintained antiviral activity at higher levels when added to the medium even after 6 h of virus infection. On the other hand, ASWPH suppressed progeny IFV-A production only when it was added at the time of virus infection in this experiments.
As described above, the most sensitive stages of replication of HSV-2 and IFV-A to ASWPH were probably very early stages such as virus adsorption to host cell surface and/or virus penetration into host cells. Hence, in order to determine whether ASWPH influences virus adsorption onto host cells, we applied ASWPH to an infectious center assay, which determined the number of cells binding virus particles at low temperature (4 C) in the presence of sample. As indicated in Figs. 2A and  3A , ASWPH showed interference with the adsorption of both HSV-2 and IFV-A. Therefore, one of the anti-HSV-2 and IFV-A targets of ASWPH is perhaps the virus-cell interaction step. An additional experiment was performed in order to determine whether ASWPH inhibited virus penetration into host cells. As shown in Figs. 2B and 3B, ASWPH also showed an inhibitory effect on HSV-2 penetration, whereas no such effect was observed in the case of IFV-A. This experimental difference between HSV-2 and IFV-A was perhaps due to their different modes of penetration. As described above, although the main anti-HSV-2 target of ASWPH was early stage of virus replication, other targets involved in replication can be assumed because ASWPH showed remarkable antiviral effects on its addition to the medium 6 h after infection when virus binding and penetration steps had already been completed. Hence, we evaluated their virucidal effects against HSV-2 and IFV-A. They had no virucidal effects as shown in Fig. 4 . This indicates that ASWPH has another mechanism of inhibition at later replication stages after virus penetration.
There is a report that a sulfated polysaccharide of extremely high molecular weight (Mw: 1:6 Â 10 7 ) was extracted from A. sacrum under alkaline condition. 18) The polysaccharide, named as sacrun, was reported to contain sulfated muramic acid as a chain constituent, and to show good absorption capacity for saline. 19) However, little information about biological effects of sacrun is available. On the other hand, it has been reported that exopolysacchraide (EPS) from A. halophytica, a related species of A. sacrum, showed inhibitory effects on influenza virus-induced pneumonea in mice, 20) but the chemical characteristics of sacrun appear to be different from EPS of A. halophytica.
Present study is the first report that a high-molecularweight portion of hot water extract from A. sacrum possesses antiviral effects against HSV-2 and IFV-A. Since it is well known that HSV and IFV infections are A, Sample was added to the medium at the same time as viral infection for 1 h and throughout incubation thereafter. B, Sample was added to the medium immediately after infection. Positive controls for HSV-2 and IFV-A were acyclovir and oseltamivir, respectively. ND, not determined. All date are expressed as mean from triplicate assays. Vero cells were infected with HSV-2 at 10 PFU/cell, and MDCK cells were infected with IFV-A at 0.5 PFU/cell. ASWPH (100 mg/ml) was added at various time intervals: 3 h before infection, during infection, during infection and throughout incubation, and at 0, 1, 3, or 6 h after infection with HSV-2 (black bar), and after infection with IFV-A (white bar). At 24 h post-infection, virus yields were determined by plaque assay. The virus titer of no-drug control was taken to be 100%. Data represent mean AE SD for triplicate assays.
initiated by binding to carbohydrate receptors on the host cell surface, some polysaccharides in ASWPH might interfere with virus-cell interaction and show antiviral effects as a result. In addition, other components in ASWPH might target later replication stages after viral penetration. This indicates that ASWPH might be a useful material in prevention from infectious diseases caused by HSV-2 and by IFV-A. In virus adsorption assay, Vero cell suspensions were infected with HSV-2 in the absence and the presence of ASWPH (0.5 mg/ml) at 4 C (A). Virus-adsorbed cells were counted by infectious center assay. In virus penetration assay, Vero cell monolayers were infected with HSV-2 in the absence of ASWPH at 4 C, and then shifted to 37 C to penetrate the absorbed viruses in the presence of ASWPH (0.5 mg/ml) (B). The penetrated viruses were titrated by plaque assay. Solid circles, no drug control; open circles, 0.5 mg of ASWPH per ml. Data represent mean AE SD for triplicate assay. Asterisks indicate statistical difference compared with control: Ã p < 0:05, ÃÃ p < 0:01.
